The funding will also support regulatory activities, manufacturing scale-up, and the advancement of Omnix’s broader pipeline of engineered antimicrobial peptides. With this latest round of funding, Omnix has raised a total of $43 million since its inception in 2015. Tomer Goldberg, Vice President, Managing Director Harel Technology Investments at Harel Insurance & Finance, said: “The rise of antibiotic-resistant infections is not just a medical crisis - it’s a societal one. About Harel Insurance & FinanceHarel Insurance & Finance Group is one of Israel’s largest financial institutions, with leading positions in insurance, healthcare, and investment management. About the EIC FundThe European Innovation Council (EIC) Fund is a venture initiative of the European Commission under the Horizon Europe program.